Significance Of Detecting MCP-1 In Serum From Patients With Type 2 Diabetes And Type 2 Diabetic Patients With Macrovascular Complications

Objective: Detecting Monocyte chemoattractant protein-1 (MCP-1) in serum from patients with type 2 diabetes and type 2 diabetic patients with macrovascular complications. To explore the role of MCP-1 in the insulin resistance and type 2 diabetes , explain the mechanism of rosiglitazone protective effects on insulin resistance and type 2 diabetes . Method: MCP-1 of serum in 24 normal subjects,51 type 2 diabetic patients without complications(including 15 type 2 diabetes without complications before and after rosiglitazone maleate treatment.),45 type 2 diabetic macroangiopathy was detected by ELISA method. At the same time FPG, 2hPG, FINS, FC, GHbAlc, TC, TG, LDL-c,HDL-c,TG, UA, WBC were measured, the results of determination were analyzed statistically. Result: The serum MCP-1 in type 2 diabetic macroangiopathy was higher than that in type 2 diabetes without complications and healthy controls. Serum MCP-1 was correlated positively with FPG,FINS, GHbAlc, TC,TG, LDL-c,UA, HOMAR-IR, and blood pressure and has no correlation with HDL-C, DBP, WBC and BMI. After rosiglitazone maleate treatment , the levels of serum MCP-1 were reduced and serum GHbAlc, TC ,TG , UA, LDL-C were also decreased. Conclusion: The result indicated that MCP-1 was played an important role in the pathogenesis of insulin resistance and type 2 diabetes and its macroangiopathy. The protective effects of rosiglitazone maleate on insulin resistance and blood vessel partly attribute to its lowering of serum mcp-1. Level of MCP-1 can be used for judging state of an illness and therapy of type 2 diabetes. It have important meaning for perfecting the role of inflammation theory in type 2 diabetes and exploring new treatment method.